The global xerostomia therapeutics market size was valued at USD 650 million in 2021 and is projected to reach around USD 950 million in 2030 exhibiting a CAGR of 3.5% in the forecasted period. The rising adoption of chemotherapy and radiotherapy in cancer treatment coupled with increasing use of prescribed medications are some of the key factors projected to drive the market. Increase in the patients with diabetes around the globe impact the salivary glands. Also, consuming medicines can have a range of side effects where one of them is dry mouth. Therefore, people liable more and more and medicines are in a way backing to the growth of the xerostomia therapeutics market. Growing creativity and consciousness of the same is also endorsing the growth of the market. On the other hand, finger-prick autologous blood treatment, along with low level of awareness about the same in undersized nations can be a restraint in the growth of this market.
Chemotherapy and radiation harm the salivary gland and results in dry mouth. Chemotherapy is the most common form of treatment to cancer patients provided by oncologists and medical practitioners. According to the Centers for Disease Control & Prevention (CDC), each year around 650,000 cancer patients take chemotherapy in an outpatient oncology clinic. The American Cancer Society evaluates that 3.5 million women live with breast cancer in the U.S., as of January 1, 2016. Among women with stage IV breast cancer, 48% accept radiation and/or chemotherapy.
Easy obtainability of cost-effective medicines is among the key drivers of the market. Products comprise saliva substitute gels, mouthwashes & oral rinses, sugar-free chewing gums, lozenges, toothpastes & oral-adhering discs, patches, and melts. The price of these products range from USD 10 to 90 and the reimbursement strategies of these products are favourable. For example, Ontario Ministry of Health and Long-Term Care provides funds to patients with radiation-induced xerostomia enduring treatment with drug, Salagen, in the Exceptional Access Program (EAP).
Upsurge in use of prescription medicines is projected to definitely disturb the market growth. As per the National Institute of Dental and Craniofacial Research, over 400 medicines may cause xerostomia. Prescription medicines such as antihypertensives, antidepressants, sedatives, antiparkinson, antiemetics, and antipsychotics distress the salivary gland and results in xerostomia. Growing prevalence of diseases such as hypertension, Parkinson’s disease, diabetes, and HIV lead to use of prescription drugs, thus instigating the state of dry mouth.
The COVID-19 pandemic has modelled new problems in all aspects of an individual’s life, comprising oral health. Dry mouth has developed as one of the most common difficulties that patients from all walks of life are dealing with. COVID-19 has remained related to dry mouth as an indication. As per the article titled "Xerostomia in patients with COVID-19: a case series" published in April 2021, dry mouth seemed in 60% of circumstances 3–4 days before as a prodromal symptom and in others, simultaneously or 1–2 days after the beginning of other symptoms. In most of the cases, dry mouth improved over time after beginning treatment. The study also stated that in COVID-19 patients, xerostomia may grow before the beginning of the common symptoms. Such studies establish the occurrence of the disorder in COVID-19 patients and henceforth suggest that the request for therapeutics for dry mouth disease is estimated to grow in the near future. Consequently, COVID-19 is anticipated to have a definite effect on the growth of the market.
Type Insights
Based on the type, artificial saliva/saliva substitutes segment is projected to rule the market over the forecasted period.
The reduction of saliva in the mouth can cause the tooth decay, mouth infections, an altered sense of taste or smell, trouble in swallowing, pain, and many other difficulties. Artificial saliva is a liquid or aerosol product that is sprayed into the mouth. They are aimed to moisten and relieve the pain and uneasiness of chronic dry mouth, particularly with regular use. Many artificial saliva sprays and gels claim to work for up to two hours, and many operators need extra applications to maintain moisture in the mouth, which can significantly restrict with sleep and daily activity. Numerous saliva sprays and gels also have a reputation for strong and unpleasant flavours, though a recent increase in the use of naturally sweet xylitol has led to the obtainability of better substitutes.
Factors such as the rising burden of dry mouth disease and growing research studies are driving the growth of the market segment. For example, the article named "Artificial Saliva in Diabetic Xerostomia (ASDIX): Double Blind Trial of Aldiamed Versus Placebo" issued in July 2020, determined that the use of Aldiamed spray was presented to be more active than a placebo in the management of xerostomia in type 1 and type 2 diabetes. Such studies prove that saliva substitutes are operative for the treatment of xerostomia. The stated source also described that the dry mouth symptom is one of the most common oral complaints in patients with diabetes mellitus. Moreover, the prevalence of xerostomia and hyposalivation has been described to grow with age. The study also intends that there may be growing demand for saliva substitutes in the future years as the load of diabetes mellitus and the geriatric population is anticipated to show fast growth in the near future.
Distribution Channel Insights
On the basis of distribution channel, the xerostomia therapeutics market has been categorized into retail pharmacies, hospital pharmacies, and online pharmacies. The hospital pharmacies category is to observe higher adoption of xerostomia therapeutics during the forecasted period. This is mostly owing to the accessibility of experienced healthcare professionals & the safety & efficiency throughout the treatment procedures also increasing hospital administration of patients globally are the major aspects for the growth of the segment.
Region Insights
North America dominated the regional segment with the largest share of revenue followed by Europe. Key factors donating toward governance are growing prevalence of xerostomia and other dry mouth related diseases such as rheumatoid arthritis, Sjogren’s syndrome, and HIV combined with rise in dry mouth awareness initiatives. For example, Sjogren Syndrome Foundation of the U.S. is accountable for conducting awareness and assisting patients with xerostomia in the U.S. and Canada.
However, Asia Pacific is estimated to grow with a beneficial CAGR over the forecast period owing to rising healthcare expenditure, rise in initiatives for raising awareness, and growing prevalence of diseases such as HIV, cancer, diabetes, & Parkinson’s disease that cause dry mouth situations. Cancer rates are increasing drastically in the Asia-Pacific region. For example, as per GLOBOCAN 2020, there were 9,386,454 new cases of cancer in Asia, and it is expected to reach 14,229,878 by 2040. Developing economies, such as China and India, have implemented both health and industrial policies to inspire the domestic production of cancer drugs, which is aiming to inferior therapy costs. Lower therapy costs along with growing awareness about cancer, are intending to higher adoption of chemotherapy and radiotherapy. The growing burden of cancer leads to better adoption of radiotherapy and chemotherapy, along with the dry mouth conditions associated with the treatments. Thus, this generates the need for therapeutics for considering xerostomia, which eventually boosts the market growth in the region.
Key Companies Insights
The market for Xerostomia therapeutics is moderately competitive. With the rising applications of Xerostomia therapeutics, new players are considering to enter the market. The companies are also involved in events like joint ventures, acquisitions, partnerships, mergers, and collaborations. These activities aid in growing the effect of the players in the Xerostomia therapeutics market, ultimately boosting the market growth. Some of the key companies working in the global Xerostomia therapeutics market include:
• GlaxoSmithKline PLC
• Parnell Pharmaceuticals Inc.
• Bausch Health Companies Inc.
• 3M company
• Quest Products Inc.
• Fresenius SE & Co. KGaA
• Hikma Pharmaceuticals PLC
• Lupin Limited
• Sun Pharmaceutical Industries Ltd
• Sanofi (Chattem, Inc.)
• Synedgen Inc. (Prisyna)
• ADVANZ PHARMA Corp. Limited
• Saliwell Ltd
• Pharmascience Inc (Pendopharm)
• Other players
Some of the Recent Developments:
• In September 2021, ICPA Health Products (ICPA) announced Wet Mouth, a saliva substitute for treating people suffering from xerostomia (dry mouth).
• In February 2021, Virginia Head and Neck Therapeutics, Inc., launched Voutia, which provides continuous relief from xerostomia (chronic dry mouth). The patented, FDA-cleared device offers an exclusively new method for millions of people suffering from this painful and often debilitating condition.
Segments
By Type
• Artificial Saliva/Saliva Substitutes
• Salivary Stimulants
By Product
• Drugs
• Salivary Pens
• Other Product Types
By Distribution Channel
• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies
By Geography
• North America
o U.S.
o Canada
o Mexico
• Europe
o U.K.
o Germany
o France
o Italy
o Spain
o Russia
• Asia-Pacific
o Japan
o China
o India
o Australia
o South Korea
o ASEAN
• Latin America
o Brazil
o Argentina
o Colombia
• MEA
o South Africa
o Saudi Arabia
o UAE
o Egypt